View Press Releases

XtenCHO™, the new transient expression system breaking records

September 10, 2018

STRASBOURG, FRANCE - Sep 10, 2018 - ProteoGenix managed to develop XtenCHO™, a transient expression system outperforming the productivity of the best and most popular cell lines on the market.

 

An efficient protein expression system is a major tool for the development of new therapeutics and diagnostics. Between 60 and 70% of pharmaceutical recombinant proteins are produced in CHO (Chinese Hamster Ovary) cells, which have the peculiarity of allowing easy transfections. The use of mammalian cells brings many advantages compared to other hosts such as bacteria, plants, and yeast. Among them: the ability to incorporate post-translational modifications, to express large proteins, and to adapt to high-density suspension culture in chemically-defined media. However, many factors can still influence the productivity of a mammalian cell expression system, generating a high variability in productivity results. The quality of the vectors, host cells media, screening methods and process engineering and development are some of these factors.

Thanks to a passionate and devoted scientific team and after many years of research, ProteoGenix, a leading custom assay and therapeutic antibody development service provider, developed XtenCHO™ cell line, a new expression system. To optimize its success, ProteoGenix also designed an optimized Xten transfection protocol.

ProteoGenix already significantly outperformed all of the most popular cell lines in transient expression of human IgG antibody. Such an outstanding performance makes XtenCHO™ one of the most reliable expression systems known so far for transient monoclonal antibody production.

This unique expression system is now used at ProteoGenix to produce any kind of antibodies as a service with a much lower cost which benefits to all its customers.

As a solid player in cell line engineering, ProteoGenix strives to keep improving cell lines performances for the production of monoclonal antibodies transiently as well as through stable cell lines. Stable cell lines developed at ProteoGenix are transferable to CMO's for further GMP production for clinical trial purposes.

A new cell line should be released soon, stay tuned!